SEARCH:   Advanced

Blood, Vol. 110, Issue 12, 4064-4072, December 1, 2007 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood White et al. 110: 4064 Supplemental materials for: White et al Files in this Data Supplement: Figure S1. The OCT-1 Activity was assessed in 59 patients using a second OCT-1 inhibitor Proacainamide (inhibits OCT-1 and OCT-2) (JPG, 52 KB) - As can be seen, there was excellent correlation between the OCT-1 activity as a result of Prazosin (OCT-1 and OCT-1 inhibitor) inhibition and Procainamide inhibition. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020